SCYNEXIS, Inc. (SCYX)Healthcare | Drug Manufacturers - Specialty & Generic | Jersey City, United States | NasdaqCM
5.39 USD
-0.13
(-2.355%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.39 |
Hot Take ↕ | Aug. 22, 2026, 2:18 a.m. EDT
The investment case here is fundamentally broken by a deteriorating business model, despite the allure of a cheap valuation. The company is hemorrhaging cash, with revenue collapsing by 83% year-over-year and operating margins sinking to -33%. The balance sheet, while currently liquid due to cash reserves, is bleeding equity through massive free cash flow losses. The market has rightly punished this trajectory, driving the stock down nearly 97% over the last nine years. While the reverse stock split and recent GSK payment offer temporary noise, the core thesis remains negative: a shrinking revenue base with no path to profitability. The options market confirms this pessimism, with traders aggressively buying puts to hedge against further declines. There is no catalyst strong enough to justify a long position at these levels given the structural decline in fundamentals. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.548760 |
| AutoTheta | 0.585771 |
| AutoARIMA | 0.595054 |
| AutoETS | 0.595497 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 10.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.183 |
| Excess Kurtosis | -1.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.906 |
| Revenue per Share | 2.496 |
| Market Cap | 53,628,392 |
| Forward P/E | -2.33 |
| Beta | 1.10 |
| Profit Margins | -53.26% |
| Website | https://www.scynexis.com |
As of Aug. 22, 2026, 2:18 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put volume and open interest significantly exceed call volume across all expirations, with heavy concentration in out-of-the-money strikes ($2.50 and $5.00). This 'bear put' skew suggests traders expect further weakness or volatility expansion, while the lack of significant call flow indicates a lack of conviction in a near-term recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.17464113 |
| Address1 | 1 Evertrust Plaza |
| Address2 | 13th Floor |
| All Time High | 1,200.0 |
| All Time Low | 3.53 |
| Ask | 6.95 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 93,880 |
| Average Daily Volume3 Month | 141,169 |
| Average Volume | 141,169 |
| Average Volume10Days | 93,880 |
| Beta | 1.099 |
| Bid | 3.98 |
| Bid Size | 2 |
| Book Value | 6.727 |
| City | Jersey City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.39 |
| Current Ratio | 9.654 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.67 |
| Day Low | 5.35 |
| Debt To Equity | 2.906 |
| Display Name | SCYNEXIS |
| Dividend Date | 1,594,944,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 0.078 |
| Enterprise Value | 1,490,392 |
| Eps Current Year | -2.91 |
| Eps Forward | -2.315 |
| Eps Trailing Twelve Months | -0.91 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.5439 |
| Fifty Day Average Change | 0.84609985 |
| Fifty Day Average Change Percent | 0.18620566 |
| Fifty Two Week Change Percent | -17.464113 |
| Fifty Two Week High | 10.48 |
| Fifty Two Week High Change | -5.0899997 |
| Fifty Two Week High Change Percent | -0.48568702 |
| Fifty Two Week Low | 3.53 |
| Fifty Two Week Low Change | 1.8599999 |
| Fifty Two Week Low Change Percent | 0.52691215 |
| Fifty Two Week Range | 3.53 - 10.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,399,037,400,000 |
| Float Shares | 7,359,328 |
| Forward Eps | -2.315 |
| Forward P E | -2.3282936 |
| Free Cashflow | -7,323,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 18 |
| Fullday Change | -0.13 |
| Fullday Change Percent | -2.35507 |
| Fullday Price | 5.39 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 19,216,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01995 |
| Held Percent Institutions | 0.61954 |
| Implied Shares Outstanding | 9,949,609 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,780,272,000 |
| Last Split Factor | 1:8 |
| Long Business Summary | SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. |
| Long Name | SCYNEXIS, Inc. |
| Market | us_market |
| Market Cap | 53,628,392 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_798887 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -10,235,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 54,374,613 |
| Number Of Analyst Opinions | 3 |
| Open | 5.56 |
| Operating Cashflow | -13,309,000 |
| Operating Margins | -33.08511 |
| Payout Ratio | 0.0 |
| Phone | 201 884 5485 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.39 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 5.52 |
| Price Eps Current Year | -1.8522335 |
| Price Hint | 2 |
| Price To Book | 0.80124867 |
| Price To Sales Trailing12 Months | 2.7908196 |
| Profit Margins | -0.53263 |
| Quick Ratio | 9.285 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.13000011 |
| Regular Market Change Percent | -2.3550744 |
| Regular Market Day High | 5.67 |
| Regular Market Day Low | 5.35 |
| Regular Market Day Range | 5.35 - 5.67 |
| Regular Market Open | 5.56 |
| Regular Market Previous Close | 5.52 |
| Regular Market Price | 5.39 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 56,834 |
| Return On Assets | -0.20823 |
| Return On Equity | -0.18375999 |
| Revenue Growth | -0.828 |
| Revenue Per Share | 2.496 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 9,949,609 |
| Shares Percent Shares Out | 0.042 |
| Shares Short | 417,674 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 347,559 |
| Short Name | SCYNEXIS, Inc. |
| Short Percent Of Float | 0.0428 |
| Short Ratio | 1.86 |
| Source Interval | 15 |
| State | NJ |
| Symbol | SCYX |
| Target High Price | 44.64 |
| Target Low Price | 32.0 |
| Target Mean Price | 36.54667 |
| Target Median Price | 33.0 |
| Total Cash | 54,083,000 |
| Total Cash Per Share | 5.436 |
| Total Debt | 1,945,000 |
| Total Revenue | 19,216,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.91 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.68194 |
| Two Hundred Day Average Change | -0.2919402 |
| Two Hundred Day Average Change Percent | -0.051380374 |
| Type Disp | Equity |
| Volume | 56,834 |
| Website | https://www.scynexis.com |
| Zip | 07,302-6548 |